CCTC (CCTC)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-05-08

Key Insights

Company rebranded from Catalyst Crew Technologies Corp. to LataMed AI Corp., signaling a strategic pivot toward artificial intelligence and healthcare/medical technology sectors.
Board authorized 5,000,000 shares of Series C Voting Preferred Stock with 20 votes per share, granting preferred shareholders significant voting power and potential control mechanisms over major corporate decisions.
Series C Preferred Stock includes protective provisions requiring majority approval from preferred holders before liquidation, senior equity issuance, or adverse amendments, indicating a significant dilution of common shareholder rights.
The preferred stock is non-convertible and non-redeemable with a senior liquidation preference, suggesting the company raised capital from sophisticated investors who demanded strong downside protection and governance control.

Current Report Filed: 2026-05-04

Key Insights

Company rebranded from Catalyst Crew Technologies Corp. to LataMed AI Corp., effective April 28, 2026, signaling a strategic pivot toward artificial intelligence and Latin American healthcare markets.
The company is an emerging growth company with no securities registered on major exchanges and no public trading symbol, indicating it remains a smaller, likely pre-revenue or early-stage entity.
Headquarters relocated to Caracas, Venezuela with a new principal address, representing a significant geographic and operational shift that may expose the company to geopolitical and regulatory risks in Venezuela.
The filing was signed by Kevin Rodan Levy as Chief Executive Officer, though no information is provided regarding whether this represents new leadership or continuity from the previous corporate structure.

Annual Report Filed: 2026-04-16

Key Insights

The company has accumulated significant debt, with over $700 million in convertible notes and promissory notes payable as of December 31, 2025.
The company plans to acquire JT Technologies LLC in early 2023, which could provide strategic benefits but also introduces integration and execution risks.
The company has raised additional capital through stock purchase agreements in 2023 and 2024, which have diluted existing shareholders.

Current Report Filed: 2026-04-13

Key Insights

Catalyst Crew Technologies Corp. (CCTC) has acquired intellectual property assets, including proprietary software, machine learning models, and datasets, related to its CardioAI, PulmoAI, and NeuroAI technologies.
CCTC has established a wholly-owned subsidiary, Inversiones Long 33, C.A., in Venezuela to serve as the company's operating entity in Latin America as part of its broader regional strategy.
The company has publicly announced the introduction of its CardioAI, PulmoAI, and NeuroAI platforms, which are part of its artificial intelligence-enabled healthcare technology portfolio.

Current Report Filed: 2026-04-08

Key Insights

Catalyst Crew Technologies Corp. has appointed Carlos Peña as the new Chief Financial Officer, who brings over 10 years of relevant experience in accounting, financial management, and audit support.
The company has not yet finalized the compensation arrangements for the new CFO, which will be determined at a later date.
There are no family relationships or related party transactions between the new CFO and the company's executives, indicating the appointment is an arms-length transaction.

Current Report Filed: 2026-02-25

Key Insights

Catalyst Crew Technologies Corp. is transitioning its business focus to digital health technology, including artificial intelligence-driven healthcare analytics and telehealth services.
The company has completed the acquisition of assets related to an AI healthcare analytics platform and a technology-enabled medical services platform.
The acquisition was financed through the issuance of 12 million shares of the company's restricted common stock to the seller, who is the company's sole director and executive officer.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.